Document is current

Article History

Received: 28 June 2024

Accepted: 6 August 2024

First Online: 12 September 2024

Declarations

:

: All authors received nonfinancial support (assistance with manuscript preparation) from Nucleus Global, which received funding from Vertex Pharmaceuticals Incorporated. Additional disclosures are as follows: Christian Merlo reports funding from Vertex Pharmaceuticals. Maral DerSarkissian, Catherine Nguyen, Yuqian M. Gu, and Aruna Muthukumar are current or former employees of Analysis Group Inc., which received research funding/consultancy fees from Vertex Pharmaceuticals. Yuqian M. Gu is a current employee of Kaiser Permanente. M. Alan Brookhart has served as a scientific advisory committee member for Amgen, Atara Biotherapeutics, Brigham and Women’s Hospital, Kite, Gilead, Intercept, NIDDK, and Vertex; he also has consulting fees/equity from Target RWE and equity from VitriVax and Accompany Health. Christina V. Scirica, Teja Thorat, Lisa J. McGarry, Joe Healy, and Jaime L. Rubin are current or former employees of Vertex Pharmaceuticals Incorporated and may own stock or stock options in Vertex. Joe Healy is currently employed with Regeneron Pharmaceuticals.

: The US CFFPR protocol review committee provided feedback and approved the protocol with revisions prior to study start. The Advarra Institutional Review Board, which operates in accordance with the Helsinki Declaration of 1964 and its later amendments, granted an exemption for this research project based on the scope of the research in July 2020. All the patients in the CF registry provide informed consent to include their data in the registry.